Develops drugs for sickle cell disease.
Dec 2025Revenue $0.00/yrExpenses $84.8M/yr
No trendCash runway ≈ 9 months from Jun 2026
Figures by year
When will Fulcrum Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $84.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $84.8M | −$84.8M |
| Dec 2024 | $80.0M | $102M | −$21.9M |
| Dec 2023 | $2.81M | $113M | −$111M |
| Dec 2022 | $6.34M | $119M | −$113M |
| Dec 2021 | $19.2M | $100M | −$81.1M |
| Dec 2020 | $8.82M | $80.4M | −$71.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.